1. Alkhatry, M, Al-Rifai, A, Annese, V, et al. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: a 2020 Delphi consensus. World J Gastroenterol 2020; 26: 6710–6769.
Google Scholar | Crossref | Medline2. Ng, SC, Shi, HY, Hamidi, N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769–2778.
Google Scholar | Crossref | Medline3. Turner, D, Ricciuto, A, Lewis, A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570–1583.
Google Scholar | Crossref | Medline4. Beard, JA, Franco, DL, Click, BH. The burden of cost in inflammatory bowel disease: a medical economic perspective and the future of value-based care. Curr Gastroenterol Rep 2020; 22: 6.
Google Scholar | Crossref | Medline5. Razvi, M, Lazarev, M. Optimization of biologic therapy in Crohn’s disease. Expert Opin Biol Ther 2018; 18: 263–272.
Google Scholar | Crossref | Medline6. Billioud, V, Sandborn, WJ, Peyrin-Biroulet, L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 2011; 106: 674–684.
Google Scholar | Crossref | Medline | ISI7. Gisbert, JP, Panes, J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104: 760–767.
Google Scholar | Crossref | Medline | ISI8. Qiu, Y, Chen, BL, Mao, R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFalpha dose intensification in Crohn’s disease. J Gastroenterol 2017; 52: 535–554.
Google Scholar | Crossref | Medline9. Einarson, TR, Bereza, BG, Ying Lee, X, et al. Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Curr Med Res Opin 2017; 33: 1433–1449.
Google Scholar | Crossref | Medline10. Gemayel, NC, Rizzello, E, Atanasov, P, et al. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Curr Med Res Opin 2019; 35: 1911–1923.
Google Scholar | Crossref | Medline11. Afif, W, Leighton, JA, Hanauer, SB, et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302–1307.
Google Scholar | Crossref | Medline12. Amiot, A, Grimaud, JC, Peyrin-Biroulet, L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2016; 14: 1593.e2–1601.e2.
Google Scholar | Crossref13. Italian Group for the Study of Inflammatory Bowel Disease Armuzzi, A, Biancone, L, et al. Adalimumab in active ulcerative colitis: a ‘real-life’ observational study. Dig Liver Dis 2013; 45: 738–743.
Google Scholar | Crossref | Medline14. Baert, F, Vande Casteele, N, Tops, S, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther 2014; 40: 1324–1332.
Google Scholar | Crossref | Medline15. Baki, E, Zwickel, P, Zawierucha, A. Real-life outcome of antitumor necrosis factor a in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21: 3282–3290.
Google Scholar | Crossref | Medline16. Black, CM, Yu, E, McCann, E, et al. Dose escalation and healthcare resource use among ulcerative colitis patients treated with adalimumab in English hospitals: an analysis of real-world data. PLoS ONE 2016; 11: e0149692.
Google Scholar | Crossref17. Cesarini, M, Katsanos, K, Papamichael, K, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis 2014; 46: 135–139.
Google Scholar | Crossref | Medline18. Christensen, KR, Steenholdt, C, Brynskov, J. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study. Scand J Gastroenterol 2015; 50: 1018–1024.
Google Scholar | Crossref | Medline19. Dumitrescu, G, Amiot, A, Seksik, P, et al. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Aliment Pharmacol Ther 2015; 42: 1192–1199.
Google Scholar | Crossref | Medline20. Hussey, M, Mc Garrigle, R, Kennedy, U, et al. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. Eur J Gastroenterol Hepatol 2016; 28: 217–221.
Google Scholar | Crossref | Medline21. Iborra, M, Perez-Gisbert, J, Bosca-Watts, MM, et al. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol 2017; 52: 788–799.
Google Scholar | Crossref | Medline22. Null, KD, Xu, Y, Pasquale, MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health 2017; 20: 752–761.
Google Scholar | Crossref | Medline23. Patel, H, Lissoos, T, Rubin, DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn’s disease in the United States. PLoS ONE 2017; 12: e0175099.
Google Scholar | Crossref24. Rostholder, E, Ahmed, A, Cheifetz, AS, et al. Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. Aliment Pharmacol Ther 2012; 35: 562–567.
Google Scholar | Crossref | Medline25. Sandborn, WJ, Sakuraba, A, Wang, A, et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin 2016; 32: 1233–1241.
Google Scholar | Crossref | Medline26. Taxonera, C, Iglesias, E, Muñoz, F, et al. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci 2017; 62: 481–490.
Google Scholar | Crossref | Medline27. Yamada, S, Yoshino, T, Matsuura, M, et al. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol 2014; 14: 80.
Google Scholar | Crossref | Medline28. Aguas, M, Bastida, G, Cerrillo, E, et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol 2012; 18: 4391–4398.
Google Scholar | Crossref | Medline29. Amiot, A, Hulin, A, Belhassan, M, et al. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. Clin Res Hepatol Gastroenterol 2016; 40: 90–98.
Google Scholar | Crossref | Medline30. Baert, F, Glorieus, E, Reenaers, C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis 2013; 7: 154–160.
Google Scholar | Crossref | Medline31. Bhalme, M, Sharma, A, Keld, R, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol 2013; 25: 543–549.
Google Scholar | Crossref | Medline | ISI32. Bortlik, M, Duricova, D, Malickova, K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn’s disease. J Crohns Colitis 2013; 7: 736–743.
Google Scholar | Crossref | Medline33. Bouguen, G, Laharie, D, Nancey, S, et al. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn’s disease. Inflamm Bowel Dis 2015; 21: 1047–1053.
Google Scholar | Crossref | Medline34. Bultman, E, de Haar, C, van Liere-Baron, A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients. Aliment Pharmacol Ther 2012; 35: 335–341.
Google Scholar | Crossref | Medline35. Castano-Milla, C, Chaparro, M, Saro, C, et al. Effectiveness of adalimumab in perianal fistulas in Crohn’s disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015; 49: 34–40.
Google Scholar | Crossref | Medline36. Caviglia, R, Ribolsi, M, Rizzi, M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13: 5238–5244.
Google Scholar | Crossref | Medline37. Chaparro, M, Martinez-Montiel, P, Van Domselaar, M, et al. Intensification of infliximab therapy in Crohn’s disease: efficacy and safety. J Crohns Colitis 2012; 6: 62–67.
Google Scholar | Crossref | Medline38. Chaparro, M, Panes, J, García, V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose ‘escalation’ in patients losing response. J Clin Gastroenterol 2011; 45: 113–118.
Google Scholar | Crossref | Medline39. Echarri, A, Ollero, V, Barreiro-de Acosta, M, et al. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn’s disease: predictors of efficacy in clinical practice. Eur J Gastroenterol Hepatol 2015; 27: 430–435.
Google Scholar | Crossref | Medline40. Fortea-Ormaechea, JI, Gonzalez-Lama, Y, Casis, B, et al. Adalimumab is effective in longterm real life clinical practice in both luminal and perianal Crohn’s disease. The Madrid experience. Gastroenterol Hepatol 2011; 34: 443–448.
Google Scholar | Crossref | Medline41. Gagniere, C, Beaugerie, L, Pariente, B, et al. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn’s disease. J Crohns Colitis 2015; 9: 349–355.
Google Scholar | Crossref | Medline42. Gonzalez-Lama, Y, Roman, ALS, Marin-Jimenez, I, et al. Open-label infliximab therapy in Crohn’s disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol Hepatol 2008; 31: 421–426.
Google Scholar | Crossref | Medline43. Ho, GT, Mowat, A, Potts, L, et al. Efficacy and complications of adalimumab treatment for medically-refractory Crohn’s disease: analysis of nationwide experience in Scotland (2004–2008). Aliment Pharmacol Ther 2009; 29: 527–534.
Google Scholar | Crossref | Medline44. Juillerat, P, Sokol, H, Froehlich, F. Factors associated with durable response to infliximab in Crohn’s disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis 2015; 21: 60–70.
Google Scholar | Crossref | Medline | ISI45. Karmiris, K, Paintaud, G, Noman, M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology 2009; 137: 1628–1640.
Google Scholar | Crossref | Medline | ISI46. Katz, L, Gisbert, JP, Manoogian, B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis 2012; 18: 2026–2033.
Google Scholar | Crossref | Medline | ISI47. Kiss, LS, Szamosi, T, Molnar, T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther 2011; 34: 911–922.
Google Scholar |